Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.